共查询到18条相似文献,搜索用时 515 毫秒
1.
2.
肺癌筛查和早期诊断研究进展 总被引:5,自引:0,他引:5
在我国肺癌已居肿瘤相关死亡的首位,虽然进展期肺癌患者预后很差,但大部分早期肺癌是可以治愈的.早期诊断、外科治疗仍是提高肺癌治愈率的主要手段.本文复习有关胸片(CXR)、痰细胞学、荧光纤支镜、低剂量CT(LDCT)以及分子生物学技术等在肺癌筛查和早期诊断中应用的相关文献,并对它们的效果加以评估.LDCT是目前对高危人群筛查最有效的方法,荧光纤支镜、痰液基细胞学、分子生物学技术的进展则对早期诊断有重要作用. 相似文献
3.
4.
在中国,肺癌的发病率及死亡率均居各恶性肿瘤的首位[1],多数病人在明确诊断时已经为疾病晚期.因此,寻找一种有效的肺癌早期诊断方法 是提高肺癌生存率的关键之一.对高危人群进行痰细胞学检查是肺癌各项诊断手段中最简便易行的一种方法 ,但由于多种因素的影响,它的敏感性相对较低.近年来随着新技术的发展,痰细胞学在肺癌早期诊断中的敏感性有了一定的提高.现综述如下,希望为肺癌的早期诊断提供新思路新方法 . 相似文献
5.
6.
2005例痰细胞学检查分析 总被引:1,自引:0,他引:1
痰细胞学检查为诊断肺癌的重要方法之一,近年由于工业污染及吸烟率上升等各方面因素,肺癌发病率不断上升,由前十年的第二位越过胃癌为第一位死因,所以肺癌的早期发现、早期诊断与早期治疗更显重要。在诊断早期肺癌诸多手段中痰细胞学检查阳性率高、诊断准确,且操作方法简便易行,病人无损伤、无痛苦,可反复多次检查,故为诊断肺癌,特别是早期肺癌最简单可靠的方法之一。我院于1991年门诊进行痰细胞学检查2005例,现将其结果分析如下: 相似文献
7.
肺癌作为全球发生率及死亡率最高的恶性肿瘤,随着肺结节检出率显著增加,如何对癌前结节及原位癌等进行鉴别成为早期诊断及治疗的重点及难点。从癌前到肺癌的基因异常改变是探索肺癌诊断及治疗靶点的重要依据,因此通过基因测序及相关手段探索癌前及早期肺癌基因异常改变对肺癌的早期诊断及早期干预意义重大。本文概述了肺癌早期生物标志物的最新研究进展,包括肺癌早期基因诊断标志物筛选、肺癌发生发展监控及靶向治疗靶点等方面。 相似文献
8.
肺癌的筛查和早期诊断 总被引:17,自引:0,他引:17
肺癌的筛查和早期诊断是提高肺癌治愈率、降低死亡率、延长生存期和改善肺癌患者生活质量的主要手段。简便易行、经济适用和准确可靠的检查手段是肺癌筛查和早期诊断的主要方法 ,其中引人注目的是低剂量螺旋CT和肺癌分子标志物的研究。 2 0 0 3年 8月 10~ 14日在加拿大温哥华举行的第十届世界肺癌大会上 ,有 6 0余篇论文涉及到肺癌的筛查和早期诊断方法 ,分别从胸部X线片、CT、痰细胞学、纤维支气管镜和肺癌的分子标记物等方面进行了论述 ,尤其是前几年多中心大样本的前瞻性随机对照研究 (RCT)的结果已开始有报道。现就本次大会及最近… 相似文献
9.
肺癌的诊断和治疗在近十几年取得了长足进步,然而,在全球范围内,肺癌的死亡率仍高居榜首.因此,如何更加精准地诊断早期肺癌以及发展新的、有效的肺癌治疗手段,是目前肺癌领域亟待解决的关键问题.外泌体是一种纳米级颗粒,可由包括免疫细胞、干细胞和肿瘤细胞在内的多种细胞分泌,并通过其释放的非编码RNA(non-coding RNA... 相似文献
10.
肺癌是我国发病率及死亡率最高的恶性肿瘤,其早期诊断和监测复发与转移,对提高肺癌5年生存率尤为重要循环肿瘤细胞(circulating tumor cells,CTCs)作为一种代表原发肿瘤的“液态活检标本”,有助于实时、无创性地进行组织学鉴定.CTCs检测有助于肺癌早期诊断、监测肿瘤复发与转移、判定疗效和预后,而且可能成为检测临床分子、分析耐药分子机制及解决肿瘤异质性的一种手段.本文就近年来CTCs在肺癌领域的研究进展进行综述. 相似文献
11.
12.
13.
Mao L 《Oncogene》2002,21(45):6960-6969
Despite extensive effort in improvement of diagnosis and treatment of patients with lung cancer in past three decades, the overall survival of patients with the disease remains dismal. Because the development of lung cancer takes a few decades, early diagnosis of the disease or identification of truly high-risk populations may provide us opportunity to successfully cure or prevent the disease. Recent advances in understanding biological basis of lung tumorigenesis provide new tools for detecting malignant cells or the process of malignant transformation and progression. Along with identification of molecular abnormalities in the early lung tumorigenesis, advanced molecular analytic technologies have been emerged, which may facilitate development of rapid and effective methods for early diagnosis and risk assessment. Here, I discuss recent progresses in understanding of early molecular abnormalities in lung cancer, efforts of translating laboratory findings to clinical tests, and prospective of biomarkers in lung cancer diagnosis and risk assessment. 相似文献
14.
环境因素是诱发肺癌的一个重要危险因素,吸烟者患肺癌的风险是非吸烟者的20倍。然而,仅有不到20%的吸烟者 患肺癌。近年来,多项研究表明遗传多态性在肺癌发病风险差异中发挥重要作用,主要涉及基因单核苷酸多态性和低频高外显 突变,对其深入探究可筛选肺癌易感基因和遗传高危人群,提供遗传咨询,并为临床精准诊疗提供依据。本文主要从肺癌遗传易 感性及高危人群筛查、早期肺癌诊断及晚期肺癌精准诊疗三方面内容进行概述。 相似文献
15.
《Expert review of anticancer therapy》2013,13(10):1397-1410
Lung cancer is one of the leading causes of cancer deaths in the developed world. It is grossly divided into small cell and nonsmall cell types. Depending on the stage at diagnosis, the principal means of treating nonsmall cell lung cancer are surgery, chemotherapy and/or radiotherapy. However, even when it is diagnosed at an early stage, the progression-free and overall survival rates have been disappointing compared with other cancers. In recent years, there have been a number of developments in the chemotherapeutic options for nonsmall cell lung cancer. The aim of this review is to summarize these developments, in a stage-specific manner, with respect to both standard chemotherapy and also the newer targeted therapies. 相似文献
16.
With advances in diagnostic technology, small peripheral lung cancer can be readily detected. Currently, the technique of endoscopic-surgery has become available for the treatment, and also video-assisted thoracic surgery (VATS) has proved useful for the treatment or diagnosis of early lung cancer. We report here our experience in surgical therapy with VATS and summarize recent reports which have focused on VATS for NSCLC. In the field of diagnosis, needle aspiration cytology or partial resection by VATS is available for small peripheral lesions. Either can play a significant role in staging for lung cancer or clarifying an unknown pleural effusion. VATS segmentectomy or partial resection with curability is applied to select cases. VATS lobectomy in NSCLC at clinical stage I could well be acceptable based on many recent reports and our result. This may be a valuable approach and a promising treatment for clinical stage II in the near future. 相似文献
17.
Lung cancer is one of the leading causes of cancer deaths in the developed world. It is grossly divided into small cell and nonsmall cell types. Depending on the stage at diagnosis, the principal means of treating nonsmall cell lung cancer are surgery, chemotherapy and/or radiotherapy. However, even when it is diagnosed at an early stage, the progression-free and overall survival rates have been disappointing compared with other cancers. In recent years, there have been a number of developments in the chemotherapeutic options for nonsmall cell lung cancer. The aim of this review is to summarize these developments, in a stage-specific manner, with respect to both standard chemotherapy and also the newer targeted therapies. 相似文献